DUNG TRAN: Open Payments
NPI 1851320444 · BETHLEHEM, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,367 in 40 payments from 10 companies in 2025. Trend: 2023 $1,463 · 2024 $1,119 · 2025 $2,367
Food & beverage: $2,255Education: $111
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 28 | $1,026 |
| Alkermes, Inc. | 2 | $254 |
| E.R. Squibb & Sons, L.L.C. | 2 | $238 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $220 |
| ABBVIE INC. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Neurocrine BioSciences, Inc. | 1 | $124 |
| Janssen Pharmaceuticals, Inc | 1 | $113 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
Products named: UZEDY, AUSTEDO XR, COBENFY, CAPLYTA, LYBALVI, ARISTADA, VRAYLAR, Auvelity.
Industry payments across PA — which companies pay providers there.
